April 29 (Reuters) – AstraZeneca beat first-quarter sales and profit expectations and maintained its 2026 outlook on Wednesday, as demand for its cancer drugs and investments in the U.S. and China helped the drugmaker navigate a complex geopolitical landscape.
(Reporting by Pushkala Aripaka, Sri Hari N S in Bengaluru, and Maggie Fick in London; Editing by Sonia Cheema)
